GlassScriptPhysician profile
Belfondia Pou
NPI 1063517118
$1,465.31
in general payments reported to CMS, 2019-2025
12 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $123 · 2021: $12.98 · 2022: $364 · 2023: $141 · 2024: $180 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $335.64 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $266.11 | 2019-2024 | Mounjaro |
| Leo Pharma INC. | $227.94 | 2022-2025 | Anzupgo |
| Viiv Healthcare Company | $146.76 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $134.58 | 2019 | |
| Glaxosmithkline, LLC. | $109.23 | 2023 | |
| Boston Scientific Corporation | $101.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.12 | 2022-2025 | Jardiance |
| Dexcom, INC. | $46.48 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $15.51 | 2022 | |
| Allergan, INC. | $14.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belfondia Pou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.